Subconjunctival injections of triamcinolone acetonide to treat uveitic macular edema

Abstract Background: To evaluate the efficacy and safety of subconjunctival triamcinolone acetonide (TA) injections for treating uveitic macular edema (UME). Methods: This retrospective case series study included patients with UME who received subconjunctival TA injections with a minimum follow-up period of 6 months. The main outcome measure was central macular thickness. The secondary outcome measures included best corrected visual acuity, recurrence rate and intraocular pressure. Results: In total, 68 patients (83 eyes) were enrolled in this study. The mean CMT decreased from 456.9 ± 171.1 μm at baseline to 324 ± 175.9 μm, 305.6 μm ± 147.7 μm, 331.8 ± 154.3 μm and 281.1 ± 147.6 μm at 1-, 2-, 3- and 6-months post injection, respectively (all P < 0.01). A total of 21/83 eyes exhibited elevated IOPs, of which 14 were controlled with topical IOP-lowering agents and 7 eyes underwent surgical removal of subconjunctival TA deposit. Conclusion: Subconjunctival TA injections appear to be safe and effective for UME.